Clinical Trials Sponsored by CSC Pharmaceuticals

Total 25328 results

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of HA121-28 Tablets in Advanced Biliary Tract Cancer

Biliary Tract Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study to Evaluate the Cardiac Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Malignant Tumor

Advanced Malignant Tumor

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Mass Balance and Biotransformation Study of [14C]SKLB1028 in Chinese Healthy Male Subjects

Healthy Male Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Single-dose and Multiple-dose Study to Evaluate the Pharmacokinetics and Pharmacodynamics of DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Clinical Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Recurrent/Refractory Lymphoma Subjects

Recurrent/Refractory Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Study of Desvenlafaxine in Treating Major Depressive Disorder.

Major Depressive Disorder

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Dose Escalation and Food Effect Study of SKLB1028 in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the DDI of DBPR108 With Metformin,Glibenclamide,Valsartan, or Simvastatin in Healthy Subjects

Healthy Subjects

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Clinical Trial of Trelagliptin Succinate Tablets in the Treatment of Type 2 Diabetes

Diabetes Mellitus, Type 2

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of SYHA1805 in Healthy Adult Subjects

Healthy Subjects
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of TG103 in Chinese Healthy Adult Subjects

Healthy

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of SYHA1402 in Healthy Subjects

Diabetic Peripheral Neuropathy
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Study of DP303c Administered Intravenously to Subjects With HER2-Positive in Advanced Solid Tumors

Neoplasms

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers

Venous Thrombosis
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Clinical Study of SKLB1028 Capsule in the Treatment of Recurrence/Refractory AML Patients

Acute Myeloid Leukemia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of Liposome-entrapped Mitoxantrone Hydrochloride Injection in Relapsed/Refractory Peripheral T-cell Lymphoma and NK/T-cell Lymphoma

Relapsed or Refractory Peripheral T-cell and NK/T-cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Single Dose Escalations Study of Amphotericin B Colloidal Dispersion In Healthy Subjects in China

Invasive Fungal Disease

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Clinical Trial of Mitoxantrone HCL Liposome Injection in Patients With Relapsed DLBCL and PT/NKCLs

Relapsed DLBCL and PT/NKCLs

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

A Study of Mitoxantrone Hydrochloride Liposome Injection in Advanced Recurrent or Metastatic Breast Cancer

Advanced Recurrent or Metastatic Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Comparison of Liposomal Doxorubicin and Daunorubicin-containing VDCLD Regimen in the Treatment of Adult ALL Patients

Adult Acute Lymphoblastic Leukemia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Human Bioequivalence Test (Fasting & Postprandial) of Iloperidone Tablets

Bioequivalence

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma

Poorly Differentiated Thyroid Carcinoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

Phase II Clinical Study of PLM60 for the Treatment of Cutaneous T Cell Lymphomas

Relapsed Cutaneous T Cell Lymphom

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

Schizophrenia

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Mitoxantrone Hydrochloride Liposome Injection

Malignant Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Phase I and Pharmacokinetic Study of Mitoxantrone Hydrochloride Liposome Injection

Neoplasms
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia

Acute Myeloid Leukemia
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Compare the Efficacy and Safety of HB1801 to Taxotere in Advanced Non-Small Cell Lung Cancer (NSCLC)

Locally Advanced or Metastatic Non-Small Cell Lung Cancer

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection Combined With Capecitabine Versus Capecitabine Monotherapy in Patients With Recurrent Metastatic Nasopharyngeal Carcinoma Who Failed Platinum-containing Treatment

Recurrent Metastatic Nasopharyngeal Carcinoma
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Not yet recruiting

Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)

Neuromyelitis Optica Spectrum Disorder
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Duvelisib Combined With SG001 Injection in Patient With Advanced Solid Tumors

Advanced Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study of Sirolimus for Injection (Albumin-bound) in Patients With Advanced Solid Tumors

Malignant Solid Tumors
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Efficacy of Cisplatin Micelle Injection (HA132) in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Explore the Efficacy of Alprostadil Liposomes Injection in the Prevention of CI-AKI

Contrast-induced Acute Kidney Injury

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

SKLB1028, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Newly Diagnosed Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

DP303c in Patients With HER2-positive Unresectable Locally Advanced, Relapsed, or Metastaticbreast Cancer

HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

Platinum-resistant Recurrent Ovarian Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of Docetaxel for Injection (Albumin-bound)in Different Dose Regimens in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of SG001 in Combination With Nab-Paclitaxel in Patients With Advanced Triple-Negative Breast Cancer (TNBC)

Triple Negative Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor

Pancreatic Cancer | Advanced Solid Tumor | Gastric Cancer (GC) | Gastroesophageal Junction (GEJ) Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC

Fallopian Tube Cancer | Epithelial Ovarian Cancer | Peritoneal Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Not yet recruiting

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL

Peripheral T Cell Lymphoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours

Lymphoma | Cervical Cancer | Malignant Mesothelioma | Advanced Solid Tumours | Non-Small-Cell Lung Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Advanced Bone and Soft Tissue Sarcoma

Unresectable or Metastatic Bone and Soft Tissue Sarcoma

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Patients With Advanced HER2 Negative Breast Cancer

Breast Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Terminated

A Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Relapsed or Refractory Acute Myeloid Leukemia (AML)

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study of Mitoxantrone Hydrochloride Liposome Injection in Chinese Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co....

Completed

Bioequivalence of Amphotericin B Liposome for Injection

Bioequivalence

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Active, not recruiting

A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More

SARS-CoV-2 Infection

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of DBPR108 in Subjects With Hepatic Impairment

Hepatic Impairment

China

Clinical Trials Sponsored by CSC Pharmaceuticals

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Paraguay

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations